Search Results

You are looking at 1 - 5 of 5 items for :

  • "Janus kinase inhibitor" x
  • Refine by Access: All Content x
Clear All

Oclacitinib was approved for use in the US in 2013 and is still the only Janus kinase inhibitor approved for use in veterinary medicine. While it is labeled for use by the FDA for management of pruritus associated with allergic and atopic dermatitis in canine

Restricted access
in Journal of the American Veterinary Medical Association

dermatitis in cats and dogs: a difficult disease for animals and owners . Clin Transl Allergy 2018 ; 8 : 41 . 10.1186/s13601-018-0228-5 9. Gonzales AJ Bowman JW Fici GJ , et al. Oclacitinib (APO-QUEL®) is a novel Janus kinase inhibitor with

Full access
in Journal of the American Veterinary Medical Association

editorial direction of this manuscript. References 1. Gonzales AJ , Bowman JW , Fici GJ , et al . Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy . J Vet Pharmacol Ther

Full access
in Journal of the American Veterinary Medical Association

. Ciclosporin 10 years on: indications and efficacy . Vet Rec 2014 ; 174 : 13 – 21 . 10.1136/vr.102484 40. Gonzales AJ Bowman JW Fici GJ , et al. Oclacitinib (APOQUEL) is a novel janus kinase inhibitor with activity against cytokines involved in

Full access
in Journal of the American Veterinary Medical Association

diseases are treatments that target IL-31 signaling, either using a monoclonal antibody or a Janus kinase inhibitor. 11 – 15 Similar treatments are available in humans, with the addition of therapeutic monoclonal antibodies targeting the IL-31-specific

Full access
in Journal of the American Veterinary Medical Association